iconstar paper   HIV Articles  
Back grey arrow rt.gif
DTG +TMC-278 - TMC-278 Resistance / Profile Against EFV, NNRTI Resistance
  Discusses SWORD Study - CROI: CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17)
CROI: SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1....http://www.natap.org/2012/HIV/062712_03.htm
In-vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs (06/15/09)

  iconpaperstack View Older Articles   Back to Top   www.natap.org